Global Monoclonal Antibodies Market Hit $100 Billion in 2017: Report
ROCKVILLE, Md., Feb. 21, 2018 /PRNewswire/ -- The global market for monoclonal antibodies (mAbs) – large protein molecules produced by white blood cells that seek out and destroy harmful foreign substances – topped $100 billion in 2017, according to Kalorama Information. These antibodies are finding wide application in many areas of medicine and biologic science. They have begun to replace conventional antibodies in blood banking and are used in the identification of organisms in the bacteriology laboratory. Monoclonal antibodies are also used in the diagnosis of leukemia and more recently in the treatment of malignancies. They have been used to treat transplant rejection episodes and purge bone marrow of tumor cells in bone marrow transplants. The healthcare market research firm's recent report, What's Trending in Monoclonal Antibodies, examines the several types of monoclonal antibodies on the market and in development, looking at the mAbs market by structure, by target, and by indication.
"The pharmaceutical industry has a pressing need for new therapies with novel mechanisms of action," said Bruce Carlson, Publisher of Kalorama Information. "This has benefited the monoclonal antibody market, with areas of industry concern such as drug resistance are helping to drive development."
An increasing elderly population in industrial nations over the next 25 years will be the most important factor in the growing demand for therapies. The main causes of death are cardiovascular disease, cancer, and respiratory disorders, all of which are strongly age-related. Other age-related illnesses such as osteoporosis, arthritis, Alzheimer's, and Parkinson's are major factors affecting quality of life. Mortality from cancer, diabetes, liver and kidney diseases has hardly changed, offering significant areas for research breakthroughs. Cancer, poorly served by traditional chemotherapies, is a major opportunity for biotech firms because the investment needed to develop a cancer drug is lower than that for other diseases: the field has high priority with regulatory authorities who are willing to give fast-track status on the basis of smaller (and therefore cheaper) clinical trials (a few extra months of survival could be enough to win FDA approval); the clinical community is highly concentrated; and the market size is often larger than the approved indication because of a high off-label use (for other cancers). The broad indication category of infectious disease, the third most common cause of death in many geographic regions, is also of concern and ripe for pharmaceutical development.
The first commercial monoclonal antibody was approved in 1986 as an immunosuppressant drug given to reduce acute rejection in patients with organ transplants. Following this, developers were busy finding new targets with monoclonal antibodies. Several smaller therapies reached market approval through the early 1990s. The real expansion in the market began in 1998 after the approval of three key therapies: Rituxan, Remicade, and Herceptin. These treatments began to transform the monoclonal antibody market to the $100 billion market it is today.
What's Trending in Monoclonal Antibodies (Markets by Structure, by Target, and by Indication) looks at the mAbs market in terms of regional markets and the competitive situation. Developments in regional markets are a major driver for the monoclonal antibody market. The report provides an overview of these markets, going beyond the U.S. market to discuss the European market and rest of world market, which largely encompasses the Asia Pacific region, including Japan. Further, the report provides a competitor summary. It is no surprise that the early developers of monoclonal antibodies continue to be the leaders in the segment today. Some two decades ago, Abbott (with MedImmune), Johnson & Johnson (with Centocor) and Roche (with Genentech) launched three of today's leading mAb therapies. Data provided in the report include a monoclonal antibody market summary by geographical region, 2017-2022 (United States, Europe, rest of world, global market) and monoclonal antibody competitor market share, 2017.
The report also provides analysis of the current global market, looking at the mAbs market by structure, by target, and by indication, including the following data points:
- Monoclonal Antibody Market by Structure, 2017 and Forecast 2022 (Chimeric, Humanized, Human, Others)
- Leading Products: Chimeric Structure mAb Market, 2017-2022
- Leading Products: Humanized Structure mAb Market, 2017-2022
- Leading Products: Human Structure mAb Market, 2017-2022
- Monoclonal Antibody Market by Target, 2017 and Forecast 2022 (TNF, CD20, HER2, VEGF, EGFR, PD-1, PD-L1, TNFSF11, IL12/IL23, IL17, IL6, Others)
- Monoclonal Antibody Market by Indication, 2017 and Forecast 2022 (Autoimmune, Oncology, Neurological, Respiratory, Cardio/Blood, Infection, Other)
Further, the report discusses the several factors contributing to the strong growth of the monoclonal antibodies market. Company profiles of the major participants in the mAbs market are provided as well. What's Trending in Monoclonal Antibodies (Markets by Structure, by Target, and by Indication) can be found at: https://www.kaloramainformation.com/Trending-Monoclonal-Antibodies-Structure-Target-Indication-11440829/.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.
We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog on our company website.
Press Contact:
Bruce Carlson
212 807 2262
[email protected]
SOURCE Kalorama Information
Share this article